These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38816701)

  • 1. From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
    Kamminga NCW; van der Veldt AAM; Wakkee M; van den Berge FR; van der Beek LAA; Joosen MCW; Joosse A; de Joode K; Nijsten TEC; Lugtenberg M
    BMC Cancer; 2024 May; 24(1):662. PubMed ID: 38816701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
    Kamminga NCW; van der Veldt AAM; Joosen MCW; de Joode K; Joosse A; Grünhagen DJ; Nijsten TEC; Wakkee M; Lugtenberg M
    Br J Dermatol; 2022 Sep; 187(3):381-391. PubMed ID: 35596713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy.
    Levy D; Dhillon HM; Lomax A; Marthick M; McNeil C; Kao S; Lacey J
    Support Care Cancer; 2019 May; 27(5):1845-1852. PubMed ID: 30178142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review.
    Lai-Kwon J; Inderjeeth AJ; Lisy K; Sandhu S; Rutherford C; Jefford M
    Eur J Cancer; 2023 May; 184():83-105. PubMed ID: 36907021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "There is a life before and after cancer": experiences of resuming life and unmet care needs in stage I and II melanoma survivors.
    Kamminga NCW; Kievits JEC; Wakkee M; Loon SGWV; Joosen MCW; Verver D; Munte K; Plaisier PWP; Rietjens JAC; Nijsten TEC; Lugtenberg M
    Arch Dermatol Res; 2024 Sep; 316(9):645. PubMed ID: 39325191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis.
    Watts T; Roche D; Csontos J
    J Clin Nurs; 2024 Aug; 33(8):2885-2904. PubMed ID: 38589992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
    O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
    Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
    Livingstone A; Dempsey K; Stockler MR; Howard K; Long GV; Carlino MS; Menzies AM; Morton RL
    BMC Cancer; 2021 Sep; 21(1):1014. PubMed ID: 34507552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Dravillas CE; Coleman SS; Hoyd R; Caryotakis G; Denko L; Chan CHF; Churchman ML; Denko N; Dodd RD; Eljilany I; Hardikar S; Husain M; Ikeguchi AP; Jin N; Ma Q; McCarter MD; Osman AEG; Robinson LA; Singer EA; Tinoco G; Ulrich CM; Zakharia Y; Spakowicz D; Tarhini AA; Tan AC;
    Cancer Res Commun; 2024 Aug; 4(8):1978-1990. PubMed ID: 39015091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?
    Wong A; Billett A; Milne D
    Oncologist; 2019 Nov; 24(11):e1190-e1196. PubMed ID: 31015314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
    Hossain SM; Ly K; Sung YJ; Braithwaite A; Li K
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in Immune Checkpoint Inhibitor for Melanoma Therapy.
    Boutros C; Herrscher H; Robert C
    Hematol Oncol Clin North Am; 2024 Oct; 38(5):997-1010. PubMed ID: 39048408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.
    Robert C; Marabelle A; Herrscher H; Caramella C; Rouby P; Fizazi K; Besse B
    Nat Rev Clin Oncol; 2020 Nov; 17(11):707-715. PubMed ID: 32636502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
    Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors.
    Looman EL; Cheng PF; Lai-Kwon J; Morgan L; Wakkee M; Dummer R; Dimitriou F
    Cancer Med; 2023 Jun; 12(11):12861-12873. PubMed ID: 37119050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners.
    Livingstone A; Milne D; Dempsey K; Muscat DM; Menzies AM; Howard K; Stockler MR; Morton RL
    Patient; 2021 Sep; 14(5):635-647. PubMed ID: 33759137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant immunotherapy for melanoma.
    Thomas D; Bello DM
    J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.